Protein Dephosphorylation and Protein Phosphorylation
References
1. Sun H, Tonks NK. The coordinated action of protein tyrosine phosphatases and kinases in cell signaling. Trends Biochem Sci. 1994;19:480–485.
2. Tonks NK, Diltz CD, Fischer EH. Purification of the major protein-tyrosine- phosphatases of human placenta. J Biol Chem. 1988;263:6722–6730.
3. Charbonneau H, Tonks NK, Kumar S, et al. Human placenta protein- tyrosine-phosphatase: amino acid sequence and relationship to a family of receptor-like proteins. Proc Natl Acad Sci USA. 1989;86:5252–5256.
4. Andersen JN, Mortensen OH, Peters GH, et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol. 2001;21:7117–7136.
5. Guan KL, Broyles SS, Dixon JE. A Tyr/Ser protein phosphatase encoded by vaccinia virus. Nature. 1991;350:359–362.
6. Gautier J, Solomon MJ, Booher RN, Bazan JF, Kirschner MW. cdc25 is
a specific tyrosine phosphatase that directly activates p34cdc2. Cell. 1991;67:197–211.
7. Fischer EH, Charbonneau H, Tonks NK. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science. 1991;253:401–406.
8. Sap J, Jiang YP, Friedlander D, Grumet M, Schlessinger J. Receptor tyrosine phosphatase R-PTP- mediates homophilic binding. Mol Cell Biol. 1994;14:1–9.
9. Brady-Kalnay SM, Tonks NK. Identification of the homophilic binding
site of the receptor protein tyrosine phosphatase PTP . J Biol Chem. 1994;269:28472–28477.
10.Jia Z, Barford D, Flint AJ, Tonks NK. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science. 1995;268:1754–1758.
11.Barford D, Flint AJ, Tonks NK. Crystal structure of human protein tyrosine phosphatase 1B. Science. 1994;263:1397–1404.
12.Tonks NK. PTP1B: from the sidelines to the front lines!. FEBS Lett. 2003;546:140–148.
13.Zheng XM, Wang Y, Pallen CJ. Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature. 1992;359:336–339.
14.Kenner KA, Hill DE, Olefsky JM, Kusari J. Regulation of protein tyrosine phosphatases by insulin and insulin-like growth factor I. J Biol Chem. 1993;268:25455–25462.
15.Ahmad F, Azevedo JL, Cortright R, Dohm GL, Goldstein BJ. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest. 1997;100:449– 458.
689
Signal Transduction
16.Tonks NK, Cicirelli MF, Diltz CD, Krebs EG, Fischer EH. Effect of microinjection of a low-Mr human placenta protein tyrosine phosphatase on induction of meiotic cell division in Xenopus oocytes. Mol Cell Biol. 1990;10:458–463.
17.Cicirelli MF, Tonks NK, Diltz CD, Weiel JE, Fischer EH, Krebs EG. Microinjection of a protein-tyrosine-phosphatase inhibits insulin action in Xenopus oocytes. Proc Natl Acad Sci USA. 1990;87:5514–5518.
18.Chen H, Wertheimer SJ, Lin CH, et al. Protein-tyrosine phosphatases PTP1B and syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. J Biol Chem. 1997;272:8026–8031.
19.Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. Molecular basis for the dephosphorylation of the activation segment of the insulin
receptor by protein tyrosine phosphatase 1B. Mol Cell. 2000;6:1401–1412.
20.Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 1994;372:746–754.
21.Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283:1544–1548.
22.Klaman LD, Boss O, Peroni OD, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in proteintyrosine phosphatase 1B-deficient mice. Mol Cell Biol. 2000;20:5479–5489.
23.Dixon JE, Rhodes JD. Expression of a protein tyrosine phosphatase in normal and v-src-transformed mouse 3T3 fibroblasts. J Cell Biol. 1992;117:401–414.
24.Bruskin AM, Johnson KA, Hill DE. Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene. Cancer Res. 1992;15:478–482.
25.Carpino N, Wisniewski D, Strife A, et al. p62(dok): a constitutively tyrosinephosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell. 1997;88:197–204.
26.Dube N, Cheng A, Tremblay ML. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc Natl Acad Sci USA. 2004;101:1834–1839.
27.Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA. 2002;99:11357–11362.
28.Touw IP, De Koning JP, Ward AC, Hermans MH. Signaling mechanisms of cytokine receptors and their perturbances in disease. Mol Cell Endocrinol. 2000;160:1–9.
29.Tartaglia LA. The leptin receptor. J Biol Chem. 1997;272:6093–6096.
30.Flint AJ, Tiganis T, Barford D, Tonks NK. Development of ‘substratetrapping’ mutants to identify physiological substrates of protein tyrosine phosphatases. Proc Natl Acad Sci USA. 1997;94:1680–1685.
690
Protein Dephosphorylation and Protein Phosphorylation
31.Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell. 2002;2:489–495.
32.Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2002;2:497–503.
33.Ohba M, Shibanuma M, Kuroki T, Nose K. Production of hydrogen peroxide by transforming growth factor-b1 and its involvement in induction of egr- 1 in mouse osteoblastic cells. J Cell Biol. 1994;126:1079–1088.
34.Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for
generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995;270:296–299.
35.Irani K, Xia Y, Zweier JL, et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997;275:1649–1652.
36.Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci. 2003;28:509–514.
37.Werner E, Werb Z. Integrins engage mitochondrial function for signal transduction by a mechanism dependent on Rho GTPases. J Cell Biol. 2002;158:357–368.
38.Vafa O, Wade M, Kern S, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002;9:1031–1044.
39.Mukherjee SP, Lane RH, Lynn WS. Endogenous hydrogen peroxide and peroxidative metabolism in adipocytes in response to insulin and sulfhydryl reagents. Biochem Pharmacol. 1978;27:2589–2594.
40.May JM, de Haen C. The insulin-like effect of hydrogen peroxide on pathways of lipid synthesis in rat adipocytes. J Biol Chem. 1979;254:9017– 9021.
41.Baas AS, Berk BC. Differential activation of mitogen-activated protein
kinases by H2O2 and O2 in vascular smooth muscle cells. Circ Res. 1995;77:29–36.
42.Seo MS, Kang SW, Baines IC, Tekle E, Chock PB, Rhee SG. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem. 1997;272:217–221.
43.Barrett WC, DeGnore JP, Konig S, et al. Regulation of PTP1B via glutathionylation of the active site cysteine 215. Biochemistry. 1999;38:6699–6705.
44.Blanchetot C, Tertoolen LG, den Hertog J. Regulation of receptor proteintyrosine phosphatase by oxidative stress. EMBO J. 2002;21:493–503.
45.Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002;9:387–399.
46.Lassegue B, Suh YA, Arnold RS, et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 1999;401:79–82.
691
Signal Transduction
47.Arnold RS, Shi J, Murad E, et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA. 2001;98:5550–5555.
48.Lee SR, Kwon KS, Kim SR, Rhee SG. Reversible inactivation of proteintyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem. 1998;273:15366–15372.
49.Denu JM, Tanner KG. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry. 1998;37:5633–5642.
50.Goldstein BJ, Wu X, Zilbering A, Zhu L, Lawrence JT. Hydrogen peroxide generated during cellular insulin stimulation is integral to activation of the distal insulin signaling cascade in 3T3-L1 adipocytes. J Biol Chem.
2001;28:48662–48669.
51.Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290: 84–89.
52.Neel BG, Gu H, Pao L. The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284–293.
53.Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92:441–450.
54.Yang J, Liang X, Niu T, Meng W, Zhao Z, Zhou GW. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J Biol Chem. 1998;273:28199–28207.
55.Yang J, Liu L, He D, et al. Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem. 2003;278:6516–6520.
56.Tsui HW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nature Genet. 1993;4:124–129.
57.Zhang J, Somani AK, Siminovitch KA. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signaling. Semin Immunol. 2000;12:361–378.
58.Daigle I, Yousefi S, Colonna M, Green DR, Simon HU. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med. 2002;8:62–67.
59.Perkins LA, Larsen I, Perrimon N. Corkscrew encodes a putative protein tyrosine phosphatase that functions to transduce the terminal signal from the receptor tyrosine kinase torso. Cell. 1992;70:225–236.
60.Raabe T, Riesgo-Escovar J, Liu X, Bausenwein BS, Maroy P, Hafen E. DOS, a novel pleckstrin homology domain-containing protein required for signal transduction between sevenless and Ras1 in Drosophila. Cell. 1996;85:911–920.
61.Shi ZQ, Yu DH, Park M, Marshall M, Feng GS. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol. 2006;20:1526–1536.
692
Protein Dephosphorylation and Protein Phosphorylation
62.Tang TL, Freeman RM, O’Reilly AM, Neel BG, Sokol SY. The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell. 1995;80:473–483.
63.Shi ZQ, Lu W, Feng GS. The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. J Biol Chem. 1998;273:4904–4908.
64.Saxton TM, Ciruna BG, Holmyard D, Kulkarni S, Harpal K, Rossant J, Pawson T. The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat Genet. 2000;24:420–423.
65.Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70:1555–1563.
66.Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem. 2005;280:30984–30993.
67.Andersen JN, Jansen PG, Mortensen OH, et al. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J. 2004;18:8–30.
68.Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child. 1968;116:373–380.
69.Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465–468.
70.Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34:146–150.
71.Ostman A, Yang Q, Tonks NK. Expression of DEP-1, a receptor-like protein- tyrosine-phosphatase, is enhanced with increasing cell density. Proc Natl Acad Sci USA. 1994;91:9680–9684.
72.Ruivenkamp CA, van Weze lT, Zanon C, et al. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet. 2002;31:295–300.
73.Tonks NK, Charbonneau H, Diltz CD, Fischer EH, Walsh KA. Demonstration that the leukocyte common antigen CD45 is a protein tyrosine phosphatase. Biochemistry. 1988;27:8695–8701.
74.Thomas ML, Barclay AN, Gagnon J, Williams AF. Evidence from cDNA clones that the rat leukocyte-common antigen (T200) spans the lipid bilayer and contains a cytoplasmic domain of 80,000 Mr. Cell. 1985;41: 83–93.
75.Thomas ML. Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation. Cell. 1989;58:1055–1065.
76.Byth KF, Conroy LA, Howlett S, et al. CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the
693
Signal Transduction
selection of CD4 CD8 thymocytes, and B cell maturation. J Exp Med. 1996;183:1707–1718.
77.Yoo LI, Pingel JT, Heikinheimo M, et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med. 2000;6:343–345.
78.Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, Weiss A. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell. 2000;103:1059–1070.
79.Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature. 1996;384:484–489.
80.Jove R, Hanafusa T, Hamaguchi M, Hanafusa H. In vivo phosphorylation states and kinase activities of transforming p60c-src mutants. Oncogene Res. 1989;5:49–60.
81.Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin Immunol. 2000;12:349–359.
82.Varma R, Campi G, Yokosuka T, et al. T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity. 2006;25:117–127.
83.Irie-Sasaki J, Sasaki T, Matsumoto W, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature. 2001;409: 349–354.
84.Desai DM, Sap J, Schlessinger J, Weiss A. Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell. 1993;73:541–554.
85.Jiang G, den Hertog J, Su J, Noel J, Sap J, Hunter T. Dimerization inhibits the activity of receptor-like protein-tyrosine phosphatase- . Nature. 1999;401:606–610.
86.Nam HJ, Poy F, Krueger NX, Saito H, Frederick CA. Crystal structure of the tandem phosphatase domains of RPTP LAR. Cell. 1999;97:449–457.
87.Yuvaniyama J, Denu JM, Dixon JE, Saper MA. Crystal structure of the dual specificity protein phosphatase VHR. Science. 1996;272:1328–1331.
88.Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell. 1997;90:859–869.
89.Stewart AE, Dowd S, Keyse SM, McDonald NQ. Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation. Nat Struct Biol. 2006;6:174–181.
90.Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7:833–846.
91.Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signaling. Curr Opin Cell Biol. 2000;12:186–192.
92.Arkinstall S, Nichols A. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000;14:6–16.
694
Protein Dephosphorylation and Protein Phosphorylation
93. Alessi DR, Gomez N, Moorhead G, Lewis T, Keyse SM, Cohen P. Inactivation of p42 MAP kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL100, in various cell lines. Curr Biol. 1995;55:283– 295.
94. Pulido R, Zuniga A, Ullrich A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signalregulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J. 1998;17:7337–7350.
95. Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal. 2004;16:769–779.
96. Camps M, Nichols A, Gillieron C, et al. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science. 1998;280:1212–1213.
97. Tanoue T, Adachi M, Moriguchi T, Nishida E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol. 2000;2:110–116.
98. Charles CH, Abler AS, Lau LF. cDNA sequence of a growth factorinducible immediate early gene and characterization of its encoded protein. Oncogene. 1992;7:187–190.
99. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993;75:487–493.
100.Assoian RK. Control of the G1 phase cyclin-dependent kinases by mitogenic growth factors and the extracellular matrix. Cytokine Growth Factor Rev. 1997;8:165–170.
101.Brondello JM, McKenzie FR, Sun H, Tonks NK, Pouyssegur J. Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene. 1995;10:1895–1904.
102.Sun H, Tonks NK, Bar SD. Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. Science. 1994;266:285–288.
103.Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science. 1999;286:2514–2517.
104.Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000;14:6–16.
105.Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene. 1996;13:925–931.
106.Groom LA, Sneddon AA, Alessi DR, Dowd S, Keyse SM. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J. 2006;15:3621–3632.
107.Sluss HK, Han Z, Barrett T, Davis RJ, Ip YT. A JNK signal transduction pathway that mediates morphogenesis and an immune response in
Drosophila. Genes Dev. 1996;27:45–58.
695
Signal Transduction
108.Martin-Blanco E, Gampel A, Ring J, et al. puckered encodes a phosphatase that mediates a feedback loop regulating JNK activity during dorsal closure in Drosophila. Genes Dev. 1998;12:557–570.
109.Campos-Ortega JA, Hartenstein V. Early neurogenesis in wildtype
Drosophila melanogaster. Roux’s Arch Dev Biol. 1984;193:308–325.
110.Kawakami Y, Rodriguez-Leon J, Koth CM, et al. MKP3 mediates the cellular response to FGF8 signalling in the vertebrate limb. Nat Cell Biol. 2003;5:513–519.
111.Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947.
112.Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3- kinase/AKT pathway. Proc Natl Acad Sci USA. 1999;96:4240–4245.
113.Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375–13378.
114.Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA. 1998;95:13513–13518.
115.Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999;99:323–334.
116.Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J. 3- Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol. 1998;8:69–81.
117.Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett. 2006;20:1–13.
118.Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–127.
119.Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7:263–273.
120.Nagakubo D, Taira T, Kitaura H, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun. 1997;231:509–513.
121.Trotman LC, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128:141–156.
122.Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128:157–170.
123.Cori GT, Cori CF. The enzymatic conversion of phosphorylase a to b. J Biol Chem. 1945;158:321–332.
696
Protein Dephosphorylation and Protein Phosphorylation
124.Stralfors P, Hiraga A, Cohen P. The protein phosphatases involved in cellular regulation. Purification and characterisation of the glycogenbound form of protein phosphatase-1 from rabbit skeletal muscle. Eur J Biochem. 1985;149:295–303.
125.Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem. 1989;58:453–508.
126.Cohen PT. Novel protein serine/threonine phosphatases: variety is the spice of life. Trends Biochem Sci. 1997;22:245–251.
127.Cohen PTW. Nomenclature and chromosomal localization of human protein serine/threonine phosphatase genes. Adv Prot Phosphatases. 1994;8:371–376.
128.Ishii K, Yamano H, Yanagida M. Phosphorylation of dis2 protein phosphatase at the C-terminal cdc2 consensus and its potential role in cell cycle regulation. EMBO J. 1994;13:5310–5318.
129.Dohadwala M, da Cruz e Silva EF, Hall F, et al. Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. Proc Natl Acad Sci USA. 1994;91:6408–6412.
130.Yang J, Roe SM, Cliff MJ, et al. Molecular basis for TPR domain-mediated regulation of protein phosphatase 5. EMBO J. 2005;24:1–10.
131.Yamaguchi Y, Katoh H, Mori K, Negishi M. G 12 and G 13 interact with ser/thr protein phosphatase type 5 and stimulate its phosphatase activity. Curr Biol. 2002;12:1353–1358.
132.Cohen PT, Schelling DL, da Cruz e Silva OB, Barker HM, Cohen P. The major type-1 protein phosphatase catalytic subunits are the same gene products in rabbit skeletal muscle and rabbit liver. Biochim Biophys Acta. 2006;1008:125–128.
133.Terrak M, Kerff F, Langsetmo K, Tao T, Dominguez R. Structural basis of protein phosphatase 1 regulation. Nature. 2006;429:780–784.
134.Maynes JT, Bateman KS, Cherney MM, et al. Crystal structure of the tumor-promoter okadaic acid bound to protein phosphatase-1. J Biol Chem. 2001;276:44078–44082.
135.MacKintosh C, MacKintosh RW, Inhibitors of protein kinases and phosphatases. Trends Biochem Sci. 994;19:444–448.
136.Griffith JP, Kim JL, Kim EE, et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell. 1995;82:507–522.
137.Coghlan VM, Perrino BA, Howard M, et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. Science. 1995;267:108–111.
138.Johnson DF, Moorhead G, Caudwell FB, et al. Identification of protein- phosphatase-1-binding domains on the glycogen and myofibrillar targetting subunits. Eur J Biochem. 1996;239:317–326.
697
Signal Transduction
139.Hubbard MJ, Cohen P. On target with a new mechanism for the regulation of protein phosphorylation. Trends Biochem Sci. 1993;18: 172–177.
140.Chantler PD. Calcium-dependent association of a protein complex with the lymphocyte plasma membrane: probable identity with calmodulincalcineurin. J Cell Biol. 1985;101:207–216.
141.Klee CB, Crouch TH, Krinks MH. Calcineurin: a calciumand calmodulinbinding protein of the nervous system. Proc Natl Acad Sci USA. 1979;76:6270–6273.
142.Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468–475.
143.Sihra BS, Kon OM, Durham SR, Walker S, Barnes NC, Kay AB. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax. 1997;52:447–452.
144.McKeon F. When worlds collide: immunosuppressants meet protein phosphatases. Cell. 1991;66:823–826.
145.Liu Jr J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBPFK506 complexes. Cell. 1991;66:807–815.
698